AdvisorShares Psychedelics ETF
$20.29−0.96 (−4.52%)
- 1.84%
- $46M
- +20.4%
- 7.92%
- 0M sh
- $21.23
- low $15.63high $27.02
The ETF.net PSIL Grade
F
Score 20 out of 100
- 9 of 9
Score 20 of 100 falls in the F band. A is 70 or higher, B 55 to under 70, C 40 to under 55, D 25 to under 40, F under 25.
Cost
The fund’s net expense ratio, ranked against its category.F6 out of 100Rank 9 of 9Mission
Whether the fund did what it promised, tested against its stated mandate.Risk
How the fund held up when markets fell: downside volatility, drawdowns and tail loss.F19 out of 100Rank 9 of 9Tradability
How easy the fund is to trade: daily volume, and how far its price strays from net asset value.F21 out of 100Rank 8 of 9Holdings
How concentrated the fund is, and how complete and current its disclosed holdings are.B59 out of 100Rank 5 of 9Durability
Whether the fund is likely to stay open, judged by its age, its assets and its issuer’s assets.D27 out of 100Rank 8 of 9
Our read on PSIL
FThe ticker is the thesis. PSIL is a compact, global, actively run basket of health care companies working on psychedelic medicine, with a stated goal of long-term capital appreciation in a corner of the market almost no other ETF touches.
The Fund seeks long-term capital appreciation.
Why people hold it
- One ticker, the whole theme: a global basket of roughly two dozen health care names tied to psychedelic medicine, instead of hand-picking single clinical-stage stocks.advisorshares.com
- Concentrated on purpose. At around 25 positions, the theme stays front and center rather than getting diluted inside a broad mega-cap pharma index.
- Trading since 2021, so there is multi-year live operating history behind the strategy, not a simulated one.
Worth knowing
- Expensive by pharma-ETF standards: 1.84% a year, against 0.36% at PPH and 0.35% at XPH. A niche, actively managed mandate carries a niche price tag.
- Small asset base and light trading volume. Spreads can be wide, so limit orders are the standard way to deal with a fund this thinly traded.
- Within its pharma and therapeutics peer group it sits in the bottom quartile, held back mainly by cost and tradability rather than the theme itself.
PSIL Holdings
- Stocks
- 29
- 65%
- DFTX
Sectors
- Health Care100.0%
Geography
- United States63.46%
- Canada16.46%
- United Kingdom11.50%
- Ireland7.54%
- Australia1.03%
Developed 100% · Emerging 0%
PSIL Performance
Shows how $10,000 changes over the selected period, with cash distributions reinvested at the closing price on each ex-dividend date.
Not enough history yet.
PSIL$12,042
Returns run to the Oct 12, 2026 close, with cash distributions reinvested. Each period starts on the same date that many months or years earlier. Periods over one year show the average yearly return.
| Period | PSIL |
|---|---|
| Year to date | +23.8% |
| 1 month | −14.2% |
| 3 months | −10.4% |
| 1 year | +20.4% |
| 3 years | +16.9% |
| 5 years | −23.0% |
| 10 years | — |
Calendar-year total return with cash distributions hypothetically reinvested at the ex-dividend date’s closing price. The current year shows year to date.
| Year | Return bar | PSIL |
|---|---|---|
| 2026 YTD | +23.8% | |
| 2025 | +74.1% | |
| 2024 | −19.5% | |
| 2023 | −25.3% | |
| 2022 | −67.9% | |
| 2021 | −42.0% |
PSIL in the news
PSIL Dividends
- 7.92%
- $1.68
- $1.68 per share
- Quarterly
Distribution history
PSIL Risk
- 46.9%
How it’s calculated: standard deviation
The sample standard deviation of monthly total returns, multiplied by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Total returns include reinvested distributions.
- 0.43
How it’s calculated: Sharpe ratio
Subtract each month’s Treasury-bill return from the fund’s monthly total return.
Divide the average of those excess returns by their sample standard deviation, then multiply by the square root of 12.
Uses up to 36 complete months, with at least 12 required. Each month uses the Treasury yield quoted at the end of the previous month.
- −92.8%
How it’s calculated: maximum drawdown
The largest percentage decline from an earlier peak, using total returns with reinvested distributions.
Uses up to five years through the last close, with at least 12 months required.
- 0.56
How it’s calculated: beta
The beta figure is supplied by FMP. The comparison index depends on the fund’s broad asset class.
PSIL Cost
1.84%
PSIL1.84%
- The middle half of Pharma & Therapeutics funds
- Median 0.58%
Every other Pharma & Therapeutics fund charges less.
Other funds in Pharma & Therapeutics
- BPJPInvesco Pharmaceuticals ETFExpense ratio 0.58%1 year return +34.5%
- BPBPHPortfolio Building Block World Pharma and Biotech Index ETFExpense ratio 0.13%1 year return —
- BFTXHFirst Trust Nasdaq Pharmaceuticals ETFExpense ratio 0.60%1 year return +43.8%
- COZEMRoundhill Investments - GLP-1 & Weight Loss ETFExpense ratio 0.59%1 year return +3.7%
- CTHNRAmplify Weight Loss Drug & Treatment ETFExpense ratio 0.59%1 year return +4.1%